CDK4 and breast carcinoma: In addition, Chen et al. revealed that β-thujaplicin induced G0/G1 cell-cycle arrest and significantly inhibited cyclin D1, cyclin E, and CDK4 expression in a dose-dependent manner in MCF10DCIS.com breast cancer cells [23].